Showing 71-80 of 3189 results for "".
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- Some Patients Apply Sunscreen to Nevi Onlyhttps://practicaldermatology.com/news/20130225-some_patients_apply_sunscreen_to_nevi_only/2459610/An unexpected number of patients with nevi report that they selectively apply sunscreens to moles only, and almost half of them say that a dermatologist told them to do so, according to a new study. (J Eur Acad Dermatol Venereol. e-pub). Of 1,816 European subjects surveyed (59.3% females, age 14-90
- High-Dose Vitamin D May Ease Chemotherapy- and Radiation-Related Skin Toxicities: Analysishttps://practicaldermatology.com/news/high-dose-vitamin-d-may-ease-chemotherapy-and-radiation-related-skin-toxicities/2487809/High-dose oral vitamin D may offer an option for patients experiencing chemotherapy- and radiation-induced skin toxicities, according to a multicenter case series published in JAMA Dermatology.
- Study: Off-Label Dosing Shows Limited Benefit for Brodalumab, Bimekizumab in Psoriasishttps://practicaldermatology.com/news/study-off-label-dosing-shows-limited-benefit-for-brodalumab-bimekizumab-in-psoriasis/2487623/A systematic review published in Archives of Dermatological Research suggested deviations from approved dosing schedules offered limited clinical advantage in patients with plaque psoriasis, while maintaining similar safety. Investigators reviewed randomized controlled trials and
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- REZOLVE-AD: Monthly and Quarterly Dosing of Rezpegaldesleukin Effective for ADhttps://practicaldermatology.com/news/rezolve-ad-monthly-and-quarterly-dosing-of-rezpegaldesleukin-effective-for-ad/2485647/Results from the blinded 36-week maintenance period showed rezpegaldesleukin demonstrated sustained disease control and new or deepening efficacy in moderate-to-severe atopic dermatitis (AD) with both monthly and quarterly dosing regimens, according to an announcem
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://practicaldermatology.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://practicaldermatology.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame